| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL6a1 |
| Uniprot No | P12109 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1028aa |
| 氨基酸序列 | MRAARALLPLLLQACWTAAQDEPETPRAVAFQDCPVDLFFVLDTSESVALRLKPYGALVDKVKSFTKRFIDNLRDRYYRCDRNLVWNAGALHYSDEVEIIQGLTRMPGGRDALKSSVDAVKYFGKGTYTDCAIKKGLEQLLVGGSHLKENKYLIVVTDGHPLEGYKEPCGGLEDAVNEAKHLGVKVFSVAITPDHLEPRLSIIATDHTYRRNFTAADWGQSRDAEEAISQTIDTIVDMIKNNVEQVCCSFECQPARGPPGLRGDPGFEGERGKPGLPGEKGEAGDPGRPGDLGPVGYQGMKGEKGSRGEKGSRGPKGYKGEKGKRGIDGVDGVKGEMGYPGLPGCKGSPGFDGIQGPPGPKGDPGAFGLKGEKGEPGADGEAGRPGSSGPSGDEGQPGEPGPPGEKGEAGDEGNPGPDGAPGERGGPGERGPRGTPGTRGPRGDPGEAGPQGDQGREGPVGVPGDPGEAGPIGPKGYRGDEGPPGSEGARGAPGPAGPPGDPGLMGERGEDGPAGNGTEGFPGFPGYPGNRGAPGINGTKGYPGLKGDEGEAGDPGDDNNDIAPRGVKGAKGYRGPEGPQGPPGHQGPPGPDECEILDIIMKMCSCCECKCGPIDLLFVLDSSESIGLQNFEIAKDFVVKVIDRLSRDELVKFEPGQSYAGVVQYSHSQMQEHVSLRSPSIRNVQELKEAIKSLQWMAGGTFTGEALQYTRDQLLPPSPNNRIALVITDGRSDTQRDTTPLNVLCSPGIQVVSVGIKDVFDFIPGSDQLNVISCQGLAPSQGRPGLSLVKENYAELLEDAFLKNVTAQICIDKKCPDYTCPITFSSPADITILLDGSASVGSHNFDTTKRFAKRLAERFLTAGRTDPAHDVRVAVVQYSGTGQQRPERASLQFLQNYTALASAVDAMDFINDATDVNDALGYVTRFYREASSGAAKKRLLLFSDGNSQGATPAAIEKAVQEAQRAGIEIFVVVVGRQVNEPHIRVLVTGKTAEYDVAYGESHLFRVPSYQALLRGVFHQTVSRKVALG |
| 预测分子量 | 108,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL6A1重组蛋白的3篇参考文献示例(文献标题和内容为简化概括，具体引用请核实原文)：
---
1. **标题**：*Collagen VI Assembly Requires the Presence of All Three α Chains in Recombinant Expression Systems*
**作者**：Bonaldo P, et al.
**摘要**：研究通过重组表达系统(如哺乳动物细胞)揭示了COL6A1与其他α链(COL6A2、COL6A3)共同组装形成VI型胶原蛋白微纤维的过程，强调了所有亚基对正确结构形成的必要性。
---
2. **标题**：*Recombinant Collagen VI α1 Chain Cysteine-rich Domain Inhibits Apoptosis in Muscle Cells*
**作者**：Lampe AK, Bushby KMD.
**摘要**：通过重组表达COL6A1的富含半胱氨酸结构域，发现其能够保护肌肉细胞免受凋亡，为COL6A1缺失相关肌营养不良症的治疗提供了潜在靶点。
---
3. **标题**：*Targeted Therapy for COL6A1-Related Disorders Using Engineered Recombinant Proteins*
**作者**：Cescon M, et al.
**摘要**：开发重组COL6A1蛋白并验证其在动物模型中恢复细胞外基质功能的能力，为先天性肌营养不良症和贝特莱姆肌病的基因治疗提供新策略。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“COL6A1 recombinant protein”或联系相关领域数据库获取全文。
Collagen type VI alpha 1 (COL6A1) is a key component of collagen VI, a unique extracellular matrix (ECM) protein critical for maintaining tissue integrity and cellular homeostasis. Collagen VI forms a microfibrillar network that interacts with other ECM components, bridging cells and surrounding matrices to regulate mechanical stability, cell signaling, and tissue repair. Structurally, it assembles as a heterotrimer comprising α1. α2. and α3 chains encoded by COL6A1. COL6A2. and COL6A3 genes, respectively. COL6A1. the largest chain, contains conserved collagenous domains and plays a pivotal role in the formation and function of collagen VI polymers.
Recombinant COL6A1 protein is engineered using expression systems like mammalian or insect cells to mimic native structure and post-translational modifications, such as hydroxylation and glycosylation. This allows researchers to study its biological roles in vitro or in vivo without relying on tissue-derived sources. COL6A1 dysfunction is linked to muscular dystrophies (e.g., Ullrich congenital muscular dystrophy), fibrosis, and cancer progression, making its recombinant form valuable for mechanistic studies and therapeutic exploration. For instance, it aids in investigating collagen VI-related myopathies, where mutations disrupt ECM stability, leading to muscle degeneration.
Additionally, recombinant COL6A1 is used in tissue engineering to develop biomimetic scaffolds, enhancing cell adhesion and differentiation. Its role in modulating TGF-β and integrin signaling pathways underscores its relevance in fibrosis and wound healing research. By providing a controlled, pure protein source, recombinant COL6A1 accelerates drug screening and gene therapy approaches aimed at correcting ECM abnormalities. Overall, it serves as a vital tool for unraveling collagen VI biology and developing targeted therapies for connective tissue disorders.
×
